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Conversion and degradation of [12?] labelled 
angiotensin I in isolated perfused porcine coronary 
and carotid arteries 
A H Jan Danser, Suchandana Chowdury, Larissa M de Lannoy, Willem J van der Giessen, 
Pramod R Saxena, and Maarten A D H Schalekamp 
Objective: The aims were (1) to quantitate angiotensin I to II conversion on the endothelial surface and at deeper 
sites in isolated arteries, (2) to assess whether the angiotensin II that is formed at deeper sites is released into 
the vascular lumen, and (3) to examine whether enzymes other than angiotensin converting enzyme (ACE) are 
involved in vascular angiotensin I to II conversion. Methods: Metabolism of [““I]-angiotensin I was studied 
in isolated perfused porcine coronary and carotid arteries after luminal administration of the labelled peptide 
(in the perfusion fluid) and after adventitial administration (in the organ bath). Measurements were made both in 
the presence and in the absence of captopril. Results: [‘*‘I]-angiotensin II was a major metabolite and its 
formation was virtually completely blocked by captopril, after both luminal and adventitial administration of 
[‘251]-angiotensin I. In coronary arteries (n = S), the [‘251]-angiotensin I to II conversion rate after adventitial 
administration was about half that after luminal administration. In coronary arteries (n = 6) the conversion rate 
after adventitial administration was lo-20 times lower than after luminal administration. Degradation of 
[‘251]-angiotensin I into peptides other than [‘251]-angiotensin II was also observed, with both luminal and 
adventitial administration. No [‘251]-angiotensin I or II was released into the organ bath after luminal 
administration of [1’51]-angiotensin I, and very little [‘251]-angiotensin I and II entered the lumen after adventitial 
administration of [“‘I]-angiotensin I. Conclusions: (1) Vascular angiotensin I to II conversion is not limited to 
the endothelial surface. (2) ACE is the most important, if not the only, enzyme responsible for vascular 
angiotensin I to II conversion. (3) If angiotensin I and II are formed in the adventitia or media, little of these 
peptides will enter the vascular lumen. 
Cardiovascular Research 1995;29:789-795 
T he classical view of angiotensin II, the most important biologically active product of the renin-angiotensin system, as a circulating hormone has been challenged 
in recent years. Previously it was thought that angiotensin II 
was derived solely from the conversion of circulating angio- 
tensin I by membrane bound angiotensin converting enzyme 
(ACE) of the vascular endothelium. This enzyme is identical 
with kininase II. However, there is now evidence that many 
tissues, including heart and blood vessels, contain a complete 
renin-angiotensin system”3 and that angiotensin I and angio- 
tensin II may also be generated locally, outside the 
circulating plasma.4-7 There is even good evidence that in a 
number of vascular beds angiotensin I production at tissue 
sites may contribute to the circulating levels of angiotensin I 
and II.5 ’ Angiotensin II produced in vascular tissue from 
in situ synthesised angiotensin I or from angiotensin I taken 
up from the circulation may serve functions other than the 
regulation of vascular tone. It may for instance contribute to 
the development of vascular hypertrophy.’ 
The formation of angiotensin II in the vessel wall may not 
depend on endothelial ACE only. Endothelium denuded 
rat aortic rings contain ACE activity, as determined with 
a synthetic tripeptide substrate.’ ACE has also been 
demonstrated in endothelium denuded porcine coronary 
arteries by using [‘251]-labelled angiotensin I as substrate.‘” 
In addition, angiotensin I has been found to contract 
endothelium denuded rat aortic rings.” In support of these 
findings, ACE activity has been shown in cultured rat aortic 
smooth muscle cells.12 
Several enzymes other than ACE have been described 
which can convert angiotensin I to angiotensin II in vitro.“-‘h 
A chymostatin sensitive angiotensin II generating enzyme 
(CAGE), capable of catalysing angiotensin I to II 
conversion, has been isolated from aortic tissue of dog, 
monkey, and man.17 ” This enzyme is localised mainly in 
the adventitia,‘” and is thought to be identical with an 
angiotensin II forming chymase which has recently 
been discovered in human heart tissue.‘” *’ Human heart 
chymase is a serine proteinase with high specificity for 
angiotensin I. Chymase mRNA is expressed in endothelial 
cells and in mast cells2’ and may be induced by vascular 
injury.22 
We decided to compare angiotensin I metabolism after 
luminal and adventitial administration of [““I]-labelled 
angiotensin I to isolated perfused porcine arteries. The aim 
of the present study was (1) to quantitate angiotensin I to II 
conversion both on the endothelial surface and at deeper sites 
in isolated arteries, (2) to assess whether the angiotensin II 
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that is formed at deeper sites is released into the vascular 
lumen, and (3) to examine whether angiotensin converting 
enzymes other than ACE are involved in vascular angio- 
tensin I to II conversion. 
Blood vessel preparation 
Methods 
Carotid and left anterior descending coronary arteries were obtained 
from 20 pigs (weight 16-24 kg, crossbred Yorkshire X Landrace) during 
anaesthesia with 160 mg.kg-’ CL chloralose, which was given into the 
superior caval vein, followed by a continuous intravenous infusion of 
low dose sodium pentobarbitone (5 mg.kg-‘.h“). The pigs had been 
used for acute pharmacological experiments involving intravenous 
saline or calcitonin gene related peptide infusions. All experiments were 
performed in accordance with the Guiding principles in the care and 
use of animals as approved by the American Physiological Society and 
under the regulations of the animal care committee of the Erasmus 
University, Rotterdam, The Netherlands. 
The vessels (diameter 2-3 mm) were dissected free from surrounding 
tissue, and 1-2 cm sections without side branches were mounted 
horizontally in a double jacketed 4 ml organ bath containing Krebs 
buffer (composition in mmol.litre-‘: NaCl 118, KC1 4.7, CaCl, 2.5, 
MgSO, 1.2, NaHCO, 25, KH,PO, 1.2, and glucose 8.3) which was 
continuously gassed with 95% OZ and 5% COZ at 37°C as described 
by Hulsmann et al.‘* The vessels were perfused with carbogenated 
Krebs buffer from a 6 ml reservoir kept at 37°C in a water bath, using 
a roller pump. The flow was kept at 1 ml.min’. The perfusate was 
collected in the reservoir and reperfused through the vessel, thus 
creating a closed perfusion circuit (fig 1). This set up allowed us to 
obtain samples from both the reservoir (“Ferfusate”) and the organ bath 
(“bath fluid”) after the addition of [‘* I]-angtotensin I to either the 
perfusate reservoir or the organ bath. 
Preparation qf radiolabelled angiotensins 
Monoiodinated [‘251]-angiotensin I was prepared with the chloramine-T 
method and purified as described previously.5 The specific radioactivity 
of the [‘*51]-angiotensin I preparation was 3.6 X IO6 countsmin’ (cpm) 
pmol-’ (74 kBq.pmol-‘). [“.I]-labelled preparations of angiotensin II, 
angiotensin III, angiotensin-(3-8) angiotensin-(4-8), angiotensin-(2-lo), 
angiotensin-( t-7). and tyrosine were also made.5 
%taration and measurement of radiolabelled angiotensins 
[ --I]-angiotensin I and its metabolites were extracted from the samples 
obtained during the experiment (see below) by reversible adsorption to 
octadecylsilyl silica (SepPak Cl 8, Waters). The SepPak cartridges were 
conditioned with 4 ml methanol and equilibrated with 2 X 4 ml of cold 
water. Samples were passed through the cartridge at 4°C followed by 
a wash with 2 X 4 ml of cold water. Adsorbed angiotensins were eluted 
with 3 ml methanol into polypropylene tubes and the methanol was 
evaporated under vacuum rotation at 4°C using a Savant Speed Vat 
concentrator. 
Artery 
Roller pump 
? 
Figure 1 Schematic presentation of the experimental set up. A 1-2 
cm vessel segment is mounted in a double jacketed organ bath that 
contains Krebs buffer at 37°C. The buffer is continuously gassed 
with 95% O2 and 5% COL. The vessel lumen is constantly pe@sed 
with gassed Krebs bufler from a reservoir kept in a water bath at 
37”C, using a roller pump. Volume of the bath was 4 ml. Total 
volume of the reservoir including pump and connecting cannulas 
was 6 ml. [‘251]-labelled angiotensin I was added to the reservoir 
(“luminal administration”) or the organ bath (“adventitial 
administration “). 
[ “51]-labelled angiotensins were separated by reversed phase high 
pressure liquid chromatography (HPLC), according to the method of 
Nussberger et a1?3 using a Nucleosil Cl8 steel column of 
250 X 4.6 mm and 10 pm particle size. Mobile phase A was 0.085% 
orthophosphoric acid containing 0.02% sodium azide. Mobile phase B 
was methanol. The flow was 1.5 mlmin-’ and the working temperature 
was 45°C. SepPak methanol extracts were dissolved in 100 p,l of HPLC 
solvent (mobile phase A) and injected. Elution was performed as 
follows: 65% A/35% B from 0 to 9 mitt, followed by a linear gradient 
to 45% A/55% B until 18 min. The eluate was collected in 20 s 
fractions into polypropylene tubes, and the concentrations of 
[‘*51]-a.ngiotensin I and its radiolabelled metabolites in the HPLC 
fractions were measured in the gamma counter. 
There was virtually complete recovery of radioactivity after SepPak 
extraction. Moreover, more than 95% of [“‘I]-angiotensin I or II that 
had been added to SepPak extracts was recovered after HPLC 
separation. Results of [’ ‘I]-angiotensin I and II measurements were 
therefore not corrected for the small losses during extraction and HPLC 
separation. 
Experimental protocol 
The blood vessel preparations were allowed to equilibrate for 30 min. 
In each carotid and coronary artery two experiments were performed. 
In one experiment approximately lo6 cpm [‘*‘I]-angiotensin I were 
added to the perfusate reservoir (“luminal administration”). Samples of 
100 pl were taken from both organ bath and reservoir at t = 0, 1, 2, 5, 
10, 20, and 40 min after the addition of [“51]-angiotensin I, and were 
immediately mixed with 10 ~1 inhibitor solution containing 125 mM 
disodium EDTA and 25 mM 1, IO-phenanthroline, to inhibit ACE and 
angiotensinases, respectively. The samples were stored at -70°C and 
assayed within one week. In the second experiment [“‘I]-angiotensin I
(approximately lo6 cmp) was added to the organ bath (“adventitial 
administration”), after which 100 pl samples were taken from both 
organ bath and reservoir at t = 0, 5, 10, 20, 30, and 40 min. The samples 
were immediately mixed with inhibitor solution as described above, and 
stored at -70°C. The two experiments were performed in random order, 
and between the two experiments the Krebs buffer in the organ bath 
and reservoir was refreshed several times in order to wash out all 
radioactivity. 
In a second series of experiments, captopril was added in a 
concentration of 0.4 mM before the addition of [ *‘I]-angiotensin I. Thi\ 
concentration of captopril had previously been shown to inhibit 
ACE but not other enzymes involved in the metabolism of angio- 
tensin I.” 
After completion of the experiments the length of the vessel 
segments was measured. The vessels were then blotted on dry paper and 
weighed. The wet weight of the coronary artery segments (n= 11) 
did not differ from that of the carotid artery segments (n=9): 
70(SEM 7) mg and 99( 11) mg, respectively, and the lengths were 
likewise similar: 1.5(0. I) and I .6(0.2) cm. 
Reagents 
[IleS]-angiotensin-( I- 10) decapeptide (angiotensin I), [Ile5]-angio- 
tensin-( l-8) octapeptide (angiotensin II), and [Ile5]-angiotensin-(2-8 J 
heutaueutide (aneiotensin III) were from Bachem. IIle51-anuiotensin- 
(21ioj nonapeptide (angiotensin-(2- 10)) was from _ Senn CYhemicals. 
[IleS]-angiotensin-(3-8) hexapeptide (angiotensin-(3-8)), [IleS]-angio- 
tensin-(4-8) pentapeptide (angiotensin-(4-8)) [IleS]-angiotensin-( l-7) 
heptapeptide (angiotensin-( l-7)), and tyrosine were from Peninsula 
Laboratories. Captopril was obtained from Bristol-Myers Squibb. 
Methanol, ortho-phosphoric acid (both analytical grade), and 
I. IO-phenantroline were purchased from Merck. Water for HPLC was 
prepared with a Milli-Q system from Waters. 
Calculations 
[‘251]-angiotensin I is eliminated either by conversion to [‘?I-angio- 
tensin II by ACE or other angiotensin converting enzymes, or by 
breakdown to small biologically inactive peptides by various other 
enzymes. We refer to the latter process as “degradation” of [‘Z51]-angio- 
tensin Lz4 The first order rate constants for degradation and conversion 
of [“‘I]-angiotensin I are denoted as k, and kz. respectively. The rate 
constant for [“‘I]-angiotensin 1 elimination (k,) is taken to be equal to 
the sum of the first order rate constants for conversion and 
degradation. 
The metabolism of [‘251]-angiotensin I in a closed perfusion circuit 
can be described by the equation for a first order process, so that k,, 
can be calculated as follows: 
k., = -I/t.ln([[‘2’I]-angiotensin I],/[[“51]-angiotensin 11”) (1) 
in which [[“TI]-angiotensin I], is the concentration of [“51]-angiotensin 1 
at time t and [[‘Z51]-angiotensin I], is the concentration of [‘-‘I]-angio- 
tensin I at t = 0 (immediately after the addition of [‘*51]-angiotensin I). 
The elimination of [‘251]-angiotensin II involves degradation only. 
Experiments in pigs, in which [“‘I]-angiotensin I was infused into the 
left cardiac ventricle,‘” and experiments in humans, in which 
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[‘251]-angiotensin I and [“‘I]-angiotensin II were infused in a peripheral 
vein,25 did not show a difference between the rate constants for 
degradation of infused [‘251]-angiotensin I and infused [“‘I]-angio- 
tensin II. Results of these experiments were also compatible with the 
assumption that the rate constants of infused [‘251]-angiotensin I and 
[‘251]-angiotensin II generated from infused [‘251]-angiotensin I are not 
different. Applying these assumptions to the present experiments, k, can 
be calculated as follows: 
k, = -l/t.ln(([[‘251]-angiotensin II], + [[‘251]-angiotensin I],)/ 
[ [“‘I]-angiotensin Ilo) (2) 
in which[[ “‘I]-angiotensin II], is the concentration of [ ‘*‘I]-angio- 
tensin II at time t. 
Finally, k2 can be obtained by subtracting k, (calculated with for- 
mula 2) from k, (calculated with formula 1). 
[‘251]-angiotensin I metabolic clearance rates due to degradation plus 
conversion or due to degradation or conversion seuaratelv were 
calculated by multiplying k,-+ k, , k, , or k, respectively w&h the ‘volume 
of distribution (6 ml for luminal administration. 4 ml for adventitial 
administration).‘ No corrections were made for the small volume 
changes that occurred as a consequence of fluid sampling for 
angiotensin measurements. 
The percentage of [‘251]-angiotensin I metabolism due to conversion 
is defined as follows: 
Contribution of conversion to metabolism (%) = [k2/(kl + k,)].lOO. 
(3) 
Statistics 
All data are reported as mean(SEM). Differences between carotid and 
coronary arteries and differences between exoeriments with and without 
captopril were evaluated for statistical signi&.nce (P c 0.05) by using 
the Mann-Whitney U test for unpaired observations. Differences in 
metabolism between luminal and adventitial administration of 
[‘*‘I]-angiotensin I were evaluated for statistical significance by using 
the Mann-Whitney U test for paired observations. 
Results 
Vascular metabolites of [‘251]-angiotensin I during luminal 
or adventitial administration of [‘251]-angiotensin I 
With luminal administration of [‘251]-angiotensin I, radio- 
activity (that is, [‘251]-angiotensin I and its radiolabelled 
metabolites) was limited to the perfusate, both in carotid and 
coronary arteries. With adventitial administration, however, 
radioactivity was not limited to the bath fluid. Some 
radioactivity reached the perfusate in coronary and carotid 
arteries during the course of the experiment. The amount of 
radioactivity in the perfusate tended to plateau after 
20-30 min at approximately OS-1.0% (carotid arteries) or 
IO-15% (coronary arteries) of total radioactivity. With both 
luminal and adventitial administration, radioactivity in 
vascular tissue, as measured after termination of the 
experiment, was marginal (approximately 1% of total 
radioactivity). Because of these low levels we did not 
attempt to measure intact [1251]-angiotensin I or II in the 
vessel wall. 
With both means of [‘251]-angiotensin I administration, 
[‘251]-angiotensin II appeared to be a major metabolite. Peaks 
with retention times corresponding to those of [‘251]-tyrosine, 
[‘251]-angiotensin-(4-8) and [‘251]-angiotensin-(2-10) could 
also be identified (fig 2). After adventitial [1251]-angiotensin I 
administration, most of the radioactivity present in the 
perfusate was found in the peak corresponding with 
[ ‘251]-tyrosine (fig 2). 
Release of [i251]-angiotensin I and II into the lumen after 
adventitial administration of [‘251]-angiotensin I 
With adventitial administration of [1251]-angiotensin I to 
coronary arteries, small quantities of [‘251]-angiotensin I and 
[ ‘251]-angiotensin II could be detected in the perfusate 20 min 
after [1251]-angiotensin I had been added to the bath fluid. At 
the end of the experiment, the levels of [1251]-angiotensin I 
and II in the perfusate were less than 10% of the levels in 
the bath (fig 2). 
No intact [ ‘251]-angiotensin I or [ ‘251]-angiotensin II could 
be detected in the perfusate during adventitial administration 
of [‘251]-angiotensin I to carotid arteries. Likewise, with 
luminal administration, both to coronary and carotid arteries, 
none of these radiolabelled peptides could be detected in the 
bath fluid (fig 2). 
Vascular [““I]-angiotensin I metabolic clearance rates 
during luminal or adventitial administration of 
[‘251]-angiotensin I 
The decrease in [‘251]-angiotensin I and the increase in 
[‘251]-angiotensin II in the perfusion fluid after luminal 
[‘251]-angiotensin I administration are shown in fig 3. The 
changes in [‘251]-angiotensin I and II in the bath fluid after 
adventitial [‘251]-angiotensin I administration are shown in 
fig 4. No major differences were detected between coronary 
and carotid arteries. [“51]-angiotensin I levels followed first 
order kinetics. The changes in [‘251]-angiotensin I and II 
levels were analysed as described under “Calculations”, and 
the best fitting curves are shown in figs 3 and 4. 
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Figure 2 Examples of high pressure liquid chromatography 
elution profiles of [‘251]-labelled angiotensins. Top panels: 
Perfusate (“lumen”) and bath fluid (“bath”) taken from a carotid 
artery 20 min afrer the addition of [‘Z51]-angiotensin I to the 
reservoir (“luminal administration”). Bottom panels: Per&sate and 
bath fluid taken from a coronary artery 40 min after the addition 
of [“‘I]-angiotensin I to the bath (“adventitial administration “). 
a = [‘251]-tyrosine; b = [‘25Z]-angiotensin-(4-8); c = [‘25/]-angio- 
tensin II; d = [‘251]-angiotensin-(2-10): e = [“‘I]-angiotensin I. 
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Figure 3 Decrease in [‘2’I]-angiotensin I (filled symbols) and 
increase in [““I]-angiotensin II (empty symbols) in the petjiisate of 
coronary (left panel) and carotid arteries (right panel) after 
luminal administration of [‘Z51]-angiotensin I in the presence 
(n = 8) or absence (n = 3) of captopril. Error bars = SEM; where 
no SEM is given it was smaller than the symbol. The solid lines are 
the bestjitting curves describing the decrease in [‘251]-angiotensin I 
and the increase in [“‘I]-angiotensin II. 
The metabolic clearance rate (MCR) of [‘251]-angiotensin I 
was higher with luminal [“51]-angiotensin I administration 
than with adventitial administration, and this was true both 
for the coronary (fig 5 and table) and carotid arteries (fig 6 
and table). In the coronary arteries the MCRs of [‘251]-angio- 
tensin 1 due to degradation and conversion were both 
significantly lower with adventitial [‘*‘I]-angiotensin I 
administration than with luminal administration (fig 5 and 
table). In the carotid arteries the MCR of [‘251]-angiotensin I 
due to degradation during luminal [‘251]-angiotensin I
administration tended to be higher than the MCR during 
adventitial administration, but the difference was not 
significant. The MCR due to conversion was higher with 
luminal administration than with adventitial administration 
in the carotid arteries (fig 6 and table). 
The percentage of [““I]-angiotensin I metabolism that could 
be attributed to [“‘I]-angiotensin I to II conversion amounted 
to 45(SEM 4)% (luminal administration, n = 8) and 37(3)% 
(adventitial administration, n = 8) in coronary arteries, and to 
62(5)% (luminal administration, n = 6) and 47(X)% (adventitial 
administration, n = 6) in carotid arteries. 
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Figure 4 Decrease in [rZ51]-angiotensin I (jilled symbols) and 
increase in [‘251]-angiotensin II (empty symbols) in the bath fluid of 
coronary (left panel) and carotid arteries (right panel) after 
adventitial administration of [“‘I]-angiotensin I in the presence 
(n = 6) or absence (n = 3) of captopril. Error bars = SEM; where 
no SEM is given it was smaller than the symbol. The solid lines are 
the best fitting curves describing the decrease in [‘251]-angiotensin I 
and the increase in [‘251]-angiotensin II. 
8 
1000 7 No captopril - - Captopril - 
P<O.O5 t’ ” ’ P<O.O5 0 
i 
0 
-e 
0 
0 
;b 
0 
Luminal Adventitial Luminal Adventitial 
application application application application 
Figure 5 Metabolic clearance rate of [‘2’I]-angiotensin I due to 
degradation (filled symbols) and conversion (empty symbols) in 
coronary arteries after luminal or adventitial [‘2’I]-angiotensin I 
administration in the absence (left panel) and presence (right 
panel) of captopril. Geometric means are shown with horizontal 
bars. 
Effect of captopril on vascular [‘251]-angiotensin I 
metabolic clearance rates during Iuminal or adventitial 
administration of [‘251]-angiotensin I 
Captopril reduced the [‘251]-angiotensin II peak in the HPLC 
fractions to values close to the background (figs 3 and 4). 
The peak corresponding with [‘251]-angiotensin-(4-8) became 
undetectable. In the presence of captopril, the peaks cor- 
responding with [‘*‘I]-tyrosine and [‘251]-angiotensin-(2- 10) 
were the main metabolites of [‘251]-angiotensin I, both with 
luminal and adventitial [‘2’I]-angiotensin I administration. 
Consequently, the MCR of [‘251]-angiotensin I due to 
conversion fell to very low levels after captopril, with both 
luminal and adventitial [ ‘251]-angiotensin I administration 
(figs 5 and 6). Captopril had little effect on [‘251]-angio- 
tensin I degradation. 
Ratio between the vascular metabolic clearance rate (MCR) of 
[‘251]-angiotensin I during adventitial administration and during 
luminal administration. Values are means(SEM). 
MCR adventitial/MCR luminal 
MCR due to MCR due to MCR due to 
degradation degradation conversion 
and conversion 
Coronary artery (n = 8) 0.5 1(0.09)* 0.62(0.1 l)* 0.44(0.14 I* 
Carotid artery (n = 6) 0.13(0.05)” 0.64(0.26) 0.06(0.01)* 
*P< 0.05 for difference from 1.00 (Mann-Whitney U test for paired 
observations). 
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Figure 6 Metabolic clearance rate of [‘2SI]-angiotensin I due to 
degradation (filled symbols) and conversion (empty symbols) in 
carotid arteries after luminal or adventitial [‘2’I]-angiotensin I
administration in the absence (left panel) and presence (right 
panel) of captopril. Geometric means are shown with horizontal 
bars. 
With captopril, the percentage of [‘2SI]-angiotensin I 
metabolism that could be attributed to [‘251]-angiotensin I to 
II conversion amounted to 16(7)% (luminal administration, 
n = 3; P < 0.05 for the difference with the experiments in the 
absence of captopril) and 9(4)% (adventitial administration; 
P < 0.05) in coronary arteries, and to 15(l)% (luminal 
administration, n = 3; P < 0.05) and 10( 1)% (adventitial 
administration; PcO.05) in carotid arteries. Thus after 
captopril more than 85% of [“‘I]-angiotensin I metabolism 
in the coronary and carotid arteries was due to 
degradation. 
Discussion 
Previous studies have shown that the vessel wall contains 
multiple enzymes, for example tissue plasminogen activator, 
tonin, cathepsin A, cathepsin G, CAGE, and chymase, which 
are capable of converting angiotensin I to angiotensin II 
in vitro and which cannot be blocked by ACE 
inhibitors.13-19 26 27 However, in most of these studies the 
conversion of angiotensin I to angiotensin II was studied 
using vascular tissue homogenates and it is not known to 
what extent homogenisation of the tissues may cause the 
release of several cellular enzymes that are not normally 
involved in the metabolism of angiotensins. We have 
observed that angiotensin I and II are much more rapidly 
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degraded in cardiac tissue homogenates than in the intact 
tissue.28 In published studies in which intact vessels were 
used angiotensin II formation was either not quantitated 
directly26 or measured after adding highly unphysiological 
amounts (50 pg per vessel) of angiotensin I.*’ 
In the present study we investigated angiotensin I 
metabolism under more physiological conditions, using 
intact segments of porcine coronary and carotid arteries, 
perfused with carbogenated Krebs buffer at 37°C. This 
model allowed us to administer angiotensin I to the blood 
vessel in the perfusion fluid (luminal application) or in the 
surrounding bath fluid (adventitial application). With luminal 
application, angiotensin I is primarily exposed to the 
vascular endothelium. Adventitially administered angio- 
tensin I - which most probably corresponds to the angio- 
tensin I that is formed in the vessel wall in the in vivo 
situation - may also reach the endothelium, but is primarily 
exposed to enzymes present in the media or adventitia. With 
both ways of administration, one would expect that 
endothelially produced angiotensin I metabolites would 
appear in the perfusate. 
Measurements of [‘2”I]-angiotensin I and II in the 
perfusion and bath fluids showed that [‘251]-angiotensin I to 
II conversion occurred not only after luminal [‘251]-angio- 
tensin I administration but also after adventitial adminis- 
tration, and that very little of the [‘251]-angiotensin II formed 
after adventitial [‘251]-angiotensin I administration was 
released into the perfusate. Moreover, the [‘251]-angiotensin 
II formed after luminal [‘251]-angiotensin I administration 
was released only in the perfusate. 
These findings. lend support to the concept that vascular 
conversion of angiotensin I is not limited to the luminal 
endothelial surface. Our present observation that little angio- 
tensin I and II passed through the wall of the carotid and 
coronary arteries from the lumen to the bath and vice versa, 
together with our previous work’ indicating rapid exchange 
between the angiotensins in circulating blood and the tissue 
interstitial fluid, is compatible with the idea that the 
exchange occurs mainly at the capillary level. There seems 
to be little accumulation of angiotensins in the present 
experiments because only low levels of radioactivity 
were found in the vessel segments at the end of the per- 
fusion. 
The conversion that occurs on the endothelial surface as 
well as at deeper sites appears to be mediated by ACE, 
because the ACE inhibitor captopril caused nearly complete 
inhibition of angiotensin II formation at these sites. 
Therefore, in the pig, enzymes other than ACE do not seem 
to play a major role in the conversion of circulating angio- 
tensin I. 
The evidence provided by our observations on perfused 
arteries that ACE dependent angiotensin I to II conversion is 
not limited to the endothelium extends previous studies in 
which the formation of [‘*‘I]-angiotensin II was followed 
during incubation of tissue pieces from endothelium denuded 
porcine coronary arteries with [‘251]-angiotensin I.” From 
these studies it was calculated that approximately 25% of the 
vascular ACE was extraendothelial. Similar findings have 
been reported for the rat aorta; de-endothelialisation of this 
vessel resulted in a 30% decrease in ACE activity of aortic 
tissue homogenates, suggesting that 70% of rat aortic ACE 
is situated outside the endothelium.’ The higher contribution 
of extraendothelial sites to angiotensin I to II conversion in 
the rat aorta might be related to the localisation of ACE in 
the smooth muscle layer. ” Radioligand binding studies have 
shown that ACE in the porcine carotid artery and in the 
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human internal mammary artery is found mainly in the 
endothelial layer and in the adventitia.29 3o These species 
differences in ACE localisation may partially explain the 
conflicting data concerning the effects of ACE inhibitors on 
myointimal proliferation after vascular injury. In the rat, the 
myointimal proliferative response to endothelial damage of 
the carotid artery was prevented by ACE inhibitor 
treatment.3’ This could not be confirmed in the pig3’ and 
likewise in humans the use of ACE inhibitors for the 
prevention of restenosis after angioplasty proved to be 
ineffective.3’ 34 It should be noted, however, that the doses 
used in the rat experiments were up to 70 times higher than 
those used in man. 
The possibility that our results might be explained by 
endothelial ACE activity of the adventitial vasa vasorum29 
must be addressed. Our observations that, with adventitial 
administration of [?I-angiotensin I, little of the peptide 
entered into the vascular perfusate and that [‘251]-angio- 
tensin II formed in the vascular lumen did not enter into the 
surrounding bath fluid make it unlikely that conversion at the 
luminal surface of the vasa vasorum is a major source of 
the [‘251]-angiotensin II found in the bath fluid. 
The [‘251]-angiotensin I to II conversion rates we measured 
after adventitial administration of [‘251]-angiotensin I may not 
be representative of the in vivo conversion rates. In the 
normal in vivo situation angiotensin I within the vascular 
tissue may have been taken up from the circulating blood or 
may have been formed locally in the tissue at extracellular 
and intracellular sites. Blood derived angiotensin I and 
locally formed angiotensin I are most probably metabolised 
differently, since blood derived angiotensin I has to pass the 
endothelial barrier which is rich in converting and degrading 
enzymes. 
Our study clearly shows that ACE present in the adven- 
titia or media is functionally active. One characteristic 
component of the adventitia is the noradrenergic nerve 
endings which are located at the adventitial-medial border. 
Angiotensin II produced by ACE in the vicinity of the nerve 
endings could act presynaptically to facilitate noradrenaline 
release. Angiotensin II mediated facilitation of neuro- 
transmitter release has been shown in a number of 
vascular preparations. 35 ” It is further possible that angio- 
tensin II formed locally within the vascular media is 
involved in the induction of medial hypertrophy.* 
Key terms: angiotensin; angiotensin converting enzyme; captopril; 
endothelium; renin: blood vessel wall. 
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